Equities Analysts Offer Predictions for ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at Zacks Research reduced their Q2 2026 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, February 11th. Zacks Research analyst D. Bautz now anticipates that the biotechnology company will post earnings per share of ($1.29) for the quarter, down from their prior estimate of ($1.14). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Zacks Research also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.49) EPS, Q4 2026 earnings at ($1.51) EPS, FY2026 earnings at ($4.11) EPS, FY2027 earnings at ($4.33) EPS and FY2028 earnings at ($4.33) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. During the same quarter in the previous year, the company earned ($1.39) EPS. The company’s quarterly revenue was up 10461.3% compared to the same quarter last year.

ARWR has been the topic of several other reports. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. B. Riley Financial increased their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Finally, Piper Sandler reissued an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $62.38 on Friday. The business’s fifty day simple moving average is $66.98 and its two-hundred day simple moving average is $44.73. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76. The company has a market cap of $8.74 billion, a price-to-earnings ratio of 40.77 and a beta of 1.21.

Insider Buying and Selling

In related news, Director Michael S. Perry sold 16,250 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the sale, the director owned 115,240 shares in the company, valued at approximately $7,033,097.20. This represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. This represents a 9.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 510,836 shares of company stock worth $33,603,060 in the last 90 days. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 168 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 1.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares in the last quarter. HighTower Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock valued at $8,845,000 after buying an additional 340 shares during the period. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $25,000. Finally, Oregon Public Employees Retirement Fund raised its stake in Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,614 shares of the biotechnology company’s stock worth $2,099,000 after buying an additional 430 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and $100 price target while raising several multi‑year EPS forecasts (notably FY2030 to $3.08). The firm’s continued Buy stance and bigger long‑term earnings lifts support a bullish growth narrative. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Positive Sentiment: Early commercial reports indicate a strong start for REDEMPLO — favourable initial uptake and revenue contribution from the product can materially improve near‑term top‑line and reduce reliance on future pipeline milestones. ARWR: Strong Start for REDEMPLO Commercialization…
• Neutral Sentiment: Short‑interest reports for February show anomalous/zero values (0 shares, NaN change) and a 0.0 days ratio — the data appear unreliable and do not provide a meaningful signal on bearish positioning. (No actionable short‑interest takeaway.)
• Negative Sentiment: Alongside the long‑term upgrades, HC Wainwright trimmed several near‑term forecasts and cut FY2026 estimates materially (FY2026 EPS lowered to -$2.83 from -$2.03), and made small downgrades to early‑2027 quarterly EPS. Those nearer‑term profit downgrades could weigh on expectations for upcoming quarters despite the Buy rating. Arrowhead (ARWR) analyst notes

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.